

Al
Con
(b) determining a change in expression of more than one of said polynucleotides, wherein a change in expression is indicative of anti-neoplastic activity.

Please add the following new claims:

112
Rule
1.122
50
51. (New) The process of claim 1 wherein the change in expression in step (b) comprises at least one of said genes being increased in expression and at least one of said genes being decreased in expression.

REMARKS

In response to the Restriction Requirement, Applicants respond by electing the claims of Group I (claims 1-5 and 44-49) drawn to a process for screening for agents having antineoplastic activity with traverse.


Applicants believe that the claims of Group IV, drawn to a method of treating cancer, should be combined with Group I for examination with the claims limited to use of compounds having activity in the screening claims.

The Office Action notes that allowance of the selection of 10 sequences was not proper because of the large number of sequences filed. For election of species drawn to sequences, Applicants note that an interview with the Examiner resulted in allowance of the selection of 10 sequences because the claimed invention cannot be adequately protected using only one sequence, although this may be within the actual wording of claim 1. Thus, Applicants have elected sequences denoted in the application as SEQ ID NO: 16, 87, 453, 462, 468, 651, 865, 1015, 1027 and 1051.

The GenBank accession numbers for these sequences are: 16 (AA142913), 87 (D13626), 453 (N22015), 462 (N54841), 468 (N69507), 651 (D00408), 865 (AA129757), 1015 (N22479), 1027 (N98464) and 1051 (W90146).

In accordance with the Examiner interview, Applicants have also amended claim 1 to recite use of more than one said sequence. In addition, because some of the elected sequences are up-regulated in cancer cells while some are up-regulated in normal cells, Applicants have also added new claim 51, directed to such differential change in expression.

Applicant includes herewith a request for a 3 month extension of time to respond plus a check to cover the fee. Because the extended period ends on January 26, 2003, a Sunday, the present response on Monday, January 27, 2003, is timely. The Commissioner is authorized to charge payment of any additional filing fees required under 37 CFR 1.16 associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:	
Commissioner for Patents U.S. Patent & Trademark Office Washington, DC 20231	
 Alan J. Grant, Esq.	<u>1/27/03</u> Date

Respectfully submitted,



Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744

AMENDED CLAIMS

1. (Once Amended) A process for screening a plurality of chemical compounds for anti-neoplastic activity comprising:

(a) contacting a compound with ~~a cell~~ one or more cells containing a polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 – 1067 under conditions wherein said polynucleotide is being expressed, and

(b) determining a change in expression of ~~at least~~ more than one of said polynucleotides,

wherein a change in expression is indicative of anti-neoplastic activity.